Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Kelly Kramer sold 2,806 shares of Gilead Sciences stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $127.11, for a total value of $356,670.66. Following the completion of the transaction, the director owned 1,339 shares in the company, valued at $170,200.29. The trade was a 67.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Gilead Sciences Trading Down 1.2%

Shares of NASDAQ GILD traded down $1.51 during mid-day trading on Monday, hitting $124.33. 4,958,911 shares of the company traded hands, compared to its average volume of 7,932,933. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The stock has a market capitalization of $154.25 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 0.81 and a beta of 0.32. The business has a 50 day moving average of $119.87 and a two-hundred day moving average of $114.70.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the company earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Mizuho boosted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Morgan Stanley raised their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $130.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after acquiring an additional 727,515 shares during the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.